Could NfL and GFAP redefine how clinicians track progression in MS? Dr Mark Freedman joins Dr Anne Cross to explain the ...

Explore the concept of the MS prodrome, a period with subtle symptoms before multiple sclerosis onset. Learn about early ...

Treatment with fenebrutinib in a 2-year open-label extension study led to significantly reduced disease-related inflammatory activity in those with relapsing MS, according to speaker at ECTRIMS ...

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

—Researchers in Finland concluded that deep cervical lymph node diameter is feasible as a biomarker for multiple sclerosis disease course. An accessible biomarker that tracks disease activity and ...

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

Tyruko, the first biosimilar of Tysabri, is now available in the U.S., providing a lower-cost treatment option for adults ...

Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...